Hilary Tindle, MD, MPH, associate professor of medicine at Vanderbilt University, discusses key findings and patient attitudes toward precision approaches to quitting smoking.
Patients are generally enthusiastic about precision approaches to quitting smoking in pilot studies, and randomized controlled trials (RCTs) are ongoing, said Hilary Tindle, MD, MPH, associate professor of medicine at Vanderbilt University.
Transcript
What were some of your findings from the pilot precision RCTs you participated in, and what were patient attitudes towards them?
We have conducted a couple of pilots and we're conducting a larger clinical trial now that is not finished, it's still ongoing. But in our pilot work, one was in the hospital clinic setting and another was in the community setting through the Southern Community Cohort Study, which is a longitudinal cohort of 12 states in the South that overlaps with Tobacco Nation.
We uniformly found that people are enthusiastic about precision approaches to quitting smoking, and that's across all groups. There were some groups, of course, who were a little less enthusiastic, but that's what you're going to find with any new therapy. And all that it means is that people need to see good evidence, they need to know that what they're accepting is high-value care. But in general, most people, if they're asked, would you take a blood test if your doctor could order it, and it could help choose the best medicine for you to quit smoking? Most people endorse that with a yes.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More